Mosley Wealth Management Has $303,000 Stake in Novartis AG (NYSE:NVS)

Mosley Wealth Management grew its stake in shares of Novartis AG (NYSE:NVS) by 16.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,948 shares of the company’s stock after buying an additional 420 shares during the period. Mosley Wealth Management’s holdings in Novartis were worth $303,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Legacy Investment Solutions LLC acquired a new position in Novartis in the 3rd quarter valued at approximately $28,000. Human Investing LLC bought a new stake in shares of Novartis during the fourth quarter valued at approximately $25,000. Union Bancaire Privee UBP SA acquired a new position in shares of Novartis in the fourth quarter valued at $27,000. Kestra Investment Management LLC bought a new position in Novartis in the fourth quarter worth $47,000. Finally, Clearstead Trust LLC acquired a new stake in Novartis during the fourth quarter worth $51,000. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 1.0 %

Shares of NVS opened at $112.11 on Friday. The stock has a fifty day moving average price of $106.67 and a two-hundred day moving average price of $107.41. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The company has a market cap of $229.15 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 1.70 and a beta of 0.53. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Analysts predict that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s dividend payout ratio is currently 42.69%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on NVS shares. Barclays restated an “underweight” rating on shares of Novartis in a research note on Monday, February 3rd. Morgan Stanley assumed coverage on Novartis in a report on Wednesday, February 12th. They set an “underweight” rating on the stock. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 8th. Finally, HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Novartis currently has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.